# Vitamin D is a biomarker of clinical disease severity in oral lichen planus

Sreedevi P. Unnikrishnan<sup>1</sup>, Janice Boggon<sup>2</sup>, Bernice Mclaughlin<sup>2</sup>, Maggie E. Cruickshank<sup>3</sup>, Rasha Abu-Eid<sup>1</sup>, and Karolin Hijazi<sup>1\*</sup>

<sup>1</sup> Institute of Dentistry, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.

<sup>2</sup>Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.

<sup>3</sup>Aberdeen Centre for Women's Health Research, Aberdeen Maternity Hospital, Aberdeen, UK.

\*To whom correspondence should be addressed. Tel: +44(0)1224-555153.

Email: k.hijazi@abdn.ac.uk.

**Abstract word count**: 285

Total word count (Introduction to Discussion): 3,162

**Total number of tables**: 3 in main manuscript and 1 in Appendix.

Number of References: 39

Keywords: Lichen Planus, Oral; Lichen Planus; Vitamin D; Disease Severity; Risk Factors; **Prognosis** 

**ABSTRACT** 

Oral lichen planus (OLP) is a chronic inflammatory condition known to adversely impact patient

quality of life and is associated with an increased risk of cancer. The diverse clinical

presentation and poor knowledge of clinical factors that determine the course of disease are

amongst the main challenges that hinder effective and personalised treatment for OLP

patients.

This study aimed to systematically identify clinical predictors of disease severity in OLP

patients. A cohort of patients with histologically confirmed OLP (n=89) was recruited in a cross-

sectional and single site study. A comprehensive assessment of clinical characteristics,

medical and social history, haematological parameters, vitamin D levels, and Perceived Stress

Scale (PSS-10) was carried out. Hierarchical linear regression identified the predictive value

of clinical factors to OLP disease severity measured by the Oral Disease Severity Score

(ODSS) and the Reticular/hyperkeratotic, Erosive/erythematous, Ulcerative (REU) scoring

system.

Findings revealed that extraoral lichen planus and insufficient vitamin D levels were significant

predictors of both overall and gingival disease severity of OLP. Specifically, patients with lichen

planus affecting the skin or other mucosal sites had a 5.766-unit higher OLP severity score

 $(\beta=5.766, 95\% \text{ CI}=.744-10.788, p=.025)$  than those without extraoral involvement as

measured by ODSS. Patients with insufficient vitamin D levels exhibited 5.490-unit increase

in OLP severity (β=5.490, 95% CI=1.136-9.844, p=.014) compared to those with adequate

vitamin D levels. The presence of dental plaque-induced gingivitis (β=4.833, 95% CI=.974-

8.692, p=.015), was found to be a significant factor affecting gingival disease severity.

This study revealed the importance of adequate vitamin D levels in OLP patients and suggests

embedding vitamin D pre-treatment screening to optimise management of OLP. Future

research should focus on elucidating the biological mechanisms underlying the protective

2

effects of vitamin D in OLP.

**INTRODUCTION** 

Oral lichen planus (OLP) is a chronic inflammatory disease of the stratified squamous

epithelium of the oral mucosa, characterised by distinctive clinical and histopathological

features. The global prevalence of OLP is estimated at 1% (González-Moles et al. 2021).

Women are more frequently affected than men, with a peak incidence in the fifth and sixth

decades of life (Cheng et al. 2016). The pathogenesis and aetiology of OLP remain poorly

understood, but it is thought to be a T-cell-mediated disorder (Cheng et al. 2016).

OLP presents with a spectrum of clinical subtypes with the most common clinical presentation

being bilateral, symmetrical white reticular lesions on the posterior buccal mucosa (Olson,

Rogers, Bruce 2016). Most cases of reticular OLP are asymptomatic, and incidentally

identified by dental professionals (De Rossi and Ciarrocca 2014). In approximately 10% of

cases, erosive or ulcerative lesions are confined to the gingiva, a clinical presentation known

as desquamative gingivitis (Olson, Rogers, Bruce 2016), Erosive and atrophic OLP can cause

varying degrees of pain (De Rossi and Ciarrocca 2014) and some studies have associated

these forms with an increased risk of carcinoma (Olson, Rogers, Bruce 2016). The biological

basis of inter-patient variability in the clinical presentation and course of disease of OLP is not

well understood.

Therapeutic interventions for OLP evaluated in clinical trials, include topical and systemic

corticosteroids, topical calcineurin inhibitors, retinoids and photochemotherapy, primarily with

the goal of pain reduction (Lodi et al. 2012). However, these treatments are not effective in all

OLP patients, notwithstanding that standardised measurement of efficacy is hampered by the

lack of universal severity indicators (Unnikrishnan et al. 2023). Diversity of response to

treatment is attributable to differences in host-related clinical and molecular factors.

While the exact cause of OLP remains elusive, several risk factors have been linked to the

development of this chronic inflammatory condition. These include genetic predisposition

(Gupta, S. and Jawanda 2015; Sun et al. 2000), potential involvement of infectious agents

(Baek and Choi 2017), pre-existing connective tissue diseases (De Porras-carrique et al. 2022) and other systemic conditions like diabetes mellitus (Mallah et al. 2021; Otero Rey et al. 2018), thyroid diseases (Dave, Shariff, Philipone 2020; De Porras-carrique et al. 2022; Li et al. 2017), hyperlipidaemia (Lai, Yew, Schwartz 2016) and hypertension (De Porras-Carrique, Ramos-García, González-Moles 2023). Additionally, psychological factors like anxiety, stress (Chaudhary 2004; De Porras-Carrique et al. 2021) have been implicated in OLP progression. Despite these associations, there is little or no understanding of how these risk factors influence the course of disease. This study aimed to identify clinical predictors of disease severity in OLP to inform treatment optimisation and prognosis of OLP patients.

#### **MATERIALS AND METHODS**

## Study population

Ethical approval for recruitment of OLP patients in this study was obtained from the West Midlands-Black Country Research Ethics Committee (Reference number: 21/WM/0247). Written informed consent was obtained from all participants in compliance with the Declaration of Helsinki. The study is registered at ClinicalTrials.gov. NCT05330572. This cross-sectional study was fully compliant with STROBE guidelines. Patients presenting with OLP diagnosed using Van der Meij and Van der Waal criteria (Van Der Meij and Van Der Waal 2003) at the Departments of Oral Medicine and Oral & Maxillofacial Surgery (Aberdeen Royal Infirmary) between December 2021 and December 2023 were eligible to the study. The following exclusion criteria were applied: age<18 years, current systemic steroid or immunosuppressive therapy for OLP, oral lichenoid contact reactions caused by dental materials, lichenoid drug reactions, graft-versus-host disease, other systemic inflammatory conditions associated with lichen planus-like oral lesions, isolated palatal lesions clinically consistent with Discoid Lupus Erythematosus, other concurrent oral mucosal inflammatory disorders or potentially malignant lesions, pregnancy or lactation.

Study protocol

Participants' medical and social history was recorded. Demographic and relevant clinical data (medical history, smoking status, and alcohol consumption) of study participants were collected from electronic patient records. If unavailable in electronic patient records, data were collected directly from patients during the study visit. The 10-item Perceived Stress Scale (PSS-10), a validated self-report instrument, was used to assess perceived stress levels in patients with OLP (Wiriyakijja et al. 2020). A single trained examiner carried out all oral examinations to assess OLP disease severity, oral hygiene status [Simplified Oral Hygiene Index (OHI-S)] (Greene and Vermillion 1964), number of teeth missing, and routine basic periodontal examination (Ower 2016). Gingivitis was diagnosed based on bleeding on probing sites (Chapple et al. 2018) and periodontitis based on amount of clinical attachment loss according to the 2017 classification system (Tonetti, Greenwell, Kornman 2018). Venous blood samples were collected for assessment of haematologic and biochemical parameters, including full blood count, haematinics, vitamin D. All parameters were assessed at the Laboratory Medicine diagnostic departments of Aberdeen Royal Infirmary and local reference

Assessment of clinical disease severity

ranges used.

The outcome measure was OLP disease severity measured as the Oral Disease Severity Score (ODSS) (Escudier et al. 2007) and Reticular/hyperkeratotic, Erosive/erythematous, Ulcerative (REU scoring system) (Piboonniyom et al. 2005). The ODSS is considered the most validated grading tool of disease activity in OLP, according to a recent systematic review (Unnikrishnan et al. 2023). ODSS assesses the site score and severity score of OLP-related lesions at seventeen oral mucosal subsites (Escudier et al. 2007). Gingival disease severity scores were calculated as the sum of site and activity scores (Escudier et al. 2007), confined to gingival sextants. The REU scoring system is one of the most reported scoring systems and has undergone the highest number of reliability assessments (Unnikrishnan et al. 2023).

Statistical analyses

For descriptive statistics, normally distributed variables are presented as mean ± standard

deviation (SD), and skewed variables as median and interquartile range [IQR]). Categorical

variables are summarised as frequencies (n) and percentages (%).

We employed a two-phase analytical approach to identify significant predictors of OLP disease

severity measured by ODSS. Initially, simple linear regression explored significant

associations between clinical indicators and ODSS (p < 0.05). Subsequently, hierarchical linear

regression examined the independent contributions of selected clinically relevant indicators to

ODSS, ODSS excluding pain score and REU scores. Covariate selection for the basic

regression model employed a dual approach considering both evidence of existing literature

and clinical relevance (Appendix Table 1). The basic regression model-I prioritised co-

morbidities associated with OLP as established from systematic reviews, namely diabetes

mellitus (Mallah et al. 2021; Otero Rey et al. 2018), hypothyroidism (De Porras-carrique et al.

2022; Li et al. 2017), hyperlipidaemia (Lai, Yew, Schwartz 2016) alongside clinically relevant

demographic factors (age, gender) and important confounding factors (use of medications

associated with lichenoid drug reactions, use of oral topical steroids within the past two

months) as listed in Appendix Table 1. Subsequent models incorporated additional markers of

interest individually: PSS-10 scores, extraoral manifestations of lichen planus, involvement of

typically spared oral sites, vitamin D, vitamin B12, ferritin and serum folate. Each linear

regression model quantified the incremental change (β) and 95% confidence intervals (CIs) in

disease severity associated with a unit change in the respective marker. Statistical significance

was set at p<0.05.

Similarly, for gingival lichen planus, we constructed a baseline linear regression model-I

considering key confounders such as dental plague-induced gingivitis and periodontitis

alongside relevant co-variates (age, gender, systemic comorbidities and use of oral topical

steroids). Subsequent models incorporated co-variates of interest individually (extraoral

involvement, vitamin D, and haematinics) to explore their independent associations with

gingival disease severity measured by the gingival ODSS. Each model again provided the β

and 95% CI for the incremental change in gingival severity associated with a unit change in

the respective covariate. Data were analysed using IBM SPSS Statistics v.29.0.1.0 (IBM,

Hampshire, UK).

The sample size for hierarchical linear regression was determined a priori aiming for a

statistical power of 0.90 to detect a medium effect size ( $f^2 = 0.15$ ) for the effect of exposures

of interest on the dependent variable. We considered exposures of interest as tested effects,

while the remaining eight variables were included in the basic regression model. Based on

this power calculation, a minimum sample size of 88 participants was required (G\*Power

version 3.1.9.7).

**RESULTS** 

**Characteristics of study participants** 

Eighty-Nine patients out of a total of 270 eligible OLP patients presenting consecutively to the

Oral Medicine and Oral & Maxillofacial Surgery outpatient clinics between December 2021

and December 2023 agreed to participate and were enrolled into the study. Characteristics of

7

study participants are reported in

**Table 1**. The median [IQRs] age of the study population was 66 [58 to 73] years, and 65 (73%)

patients were females. The cohort was representative of the typical OLP population: higher

prevalence of females in post-menopausal age. Seventeen participants (88.2% females)

presented with extraoral lichen planus, with a notable prevalence of genital involvement (over

two-thirds). Nearly half (47.1%) of the patients in the cohort suffered from chronic diseases.

Our cohort had a lower prevalence of vitamin D insufficiency (32.6%) and deficiency (9%)

compared to global rates (47.9% and 15.7%, respectively) (Cui et al. 2023).

The median total ODSS score was 10 (range: 0-44), indicating a mild to moderate disease

presentation. The median ODSS score, excluding the pain component, was 9 (range: 0-38),

while the median Gingival ODSS score was 1 (range: 0-18). The median REU score was 8

(range: 0-49).

Selection of clinically relevant co-variates

For exploratory analysis of clinical factors significantly associated with the severity of OLP, a

simple linear regression analysis was conducted, with OLP severity assessed using the ODSS

as the dependent variable (Appendix Table 1). Statistically significant clinical variables (p<

0.05) associated with OLP severity included diabetes mellitus, hyperlipidaemia, extraoral

manifestations of lichen planus, erosive clinical phenotype, involvement of typically spared

oral sites, recent use of oral topical steroids (within the past two months), dental plaque-

induced gingivitis and insufficient vitamin D levels (Appendix Table 1). Additional co-variates

were based on formal evidence of clinical characteristics associated with OLP or probable

confounders according to accepted clinical knowledge and irrespective of statistical

significance in exploratory analyses, namely age, gender, hypothyroidism, connective tissue

diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), other autoimmune

diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous

pemphigoid, lichen sclerosus), hypertension, coronary artery disease, inflammatory bowel

disease, history of cancer, anxiety or depression, smoking, alcohol consumption, stress levels

(PSS-10), medications associated with lichenoid drug reactions, amalgam restorations, co-

existing candidal infection, vitamin D, vitamin B12, ferritin, and serum folate levels (Appendix

Table 1).

Independent predictors of disease severity in OLP

The basic model-I (age, gender, diabetes mellitus, hypothyroidism, hyperlipidaemia, use of

medications associated with lichenoid drug reactions, erosive phenotype, use of oral topical

steroids) explained 33.0% of the variance in OLP severity and was a statistically significant

predictor of OLP severity as assessed by total ODSS (p=<.001) (Table 2). The analysis

identified three significant associations between OLP severity and the following independent

variables: hyperlipidaemia ( $\beta$ = 6.548, p=0.044); erosive phenotype ( $\beta$ =11.758, p=<.001) and

oral topical steroid use ( $\beta$ =4.926, p=0.023) (**Table 2**).

Subsequently, after adjusting for basic model co-variates, hierarchical linear regression

revealed that extraoral manifestations of lichen planus (model III, β=5.766, 95% CI=.744-

10.788, p=.025), involvement of typically spared oral sites (model IV,  $\beta$ =9.564, 95% CI= 4.873-

14.254, p=<.001) and insufficient vitamin D (model V, β=5.490, 95% CI=1.136-9.844, p=.014)

were significant predictors of disease severity (Table 2). Specifically, patients with lichen

planus affecting skin or other mucosal sites had a 5.766-unit higher OLP severity score than

those without extraoral involvement. Similarly, individuals with OLP affecting less frequent oral

subsites (palate, floor of the mouth and upper lip) (Olson, Rogers, Bruce 2016; Scully and

Carrozzo 2007) had a 9.564-unit increase in OLP severity compared to those with more typical

involvement (buccal mucosa, tongue). Finally, patients with insufficient vitamin D levels

exhibited 5.490-unit increase in OLP severity compared to those with adequate vitamin D

levels.

The predictive value of co-variates was assessed in relation to other measures of OLP

severity (ODSS excluding pain score and REU scores) to test generalisability of findings to

other grading tools. The basic model-I was a statistically significant predictor and explained

27.5% and 36.1% of the variance in OLP severity as assessed by ODSS excluding pain scores

and REU scores, respectively. Subsequent hierarchical regression in relation to ODSS excluding pain scores as outcome and adjusted for confounders, revealed the same three independent predictors as regression in relation to total ODSS, namely extraoral manifestations of lichen planus (model III, β=5.474, 95% Cl=1.005-9.943, p=.017), involvement of typically spared oral mucosal sites (model IV, β=8.191, 95% CI=3.963-12.418, p=<.001) and insufficient vitamin D levels (model V, β=5.043, 95% CI=1.168–8.919, p=.011) (**Table 2**). On the other hand, hierarchical regression in relation to REU scores, again adjusted for confounders, revealed less commonly involved oral sites (model IV, β=8.127, 95% CI=3.918-12.337, p=<.001), deficient vitamin D levels (model V, β= 7.097, 95% CI=.670-13.524, p=.031) and deplete folate levels (model VIII, β=-11.404, 95% CI=-22.175--.633, p=.038) (**Table 2**) as independent predictors.

## Independent predictors of gingival disease severity

Independent predictors of gingival disease severity were assessed separately in order to consider confounding factors specifically relevant to gingival lichen planus, namely dental plaque-induced gingivitis and periodontitis. A basic linear regression model-I (age, gender, diabetes mellitus, hypothyroidism, plaque-induced gingivitis, periodontitis, erosive phenotype, use of oral topical steroids) explained 10.0% of the variance of OLP severity as measured by gingival ODSS. In this model, dental plaque induced gingivitis (β=4.833, p=.015), and erosive phenotype (β=3.425, p=.049) were confirmed as significant predictors of gingival disease severity (Table 3). Following adjustment for basic model co-variates, hierarchical linear regression confirmed extraoral involvement (model II, β=5.052, 95% CI=1.072-9.032, p=.014), and insufficient vitamin D (model III, β=4.732, 95% CI=1.541-7.923, p=.004) as independent predictors (Table 3).

## **DISCUSSION**

The diverse clinical presentation and poor knowledge of clinical factors that determine the course of OLP are amongst the main challenges that hinder effective and personalised

treatment. In this cross-sectional study of OLP patients presenting with a spectrum of clinical severity, we revealed that extraoral manifestations of lichen planus and vitamin D were consistent clinical predictors of both overall and gingival disease severity of OLP.

The significant association between extraoral lichen planus and increased OLP severity identified in our study supports the notion that multi-site disease contributes to greater oral involvement. In our study, genital involvement, particularly vaginal-vulval lichen planus, was more prevalent than cutaneous involvement. This finding warrants further investigation to formally determine if predilection for certain extraoral sites influences OLP severity. Further, the involvement of typically spared oral mucosal sites (floor of the mouth, palate and upper lip) (Olson, Rogers, Bruce 2016; Scully and Carrozzo 2007) was a significant predictor of OLP severity. This finding suggests that the distribution of lesions to atypical mucosal sites may be associated with a more severe disease course. The involvement of atypical oral sites and, more broadly, multi-site involvement could reflect more profound T-cell-mediated immune dysregulation in OLP resulting in more severe disease manifestations.

The relationship between vitamin D status and OLP severity supports the findings of previous reports of lower vitamin D levels in OLP patients compared to controls in a range of geographical settings (Aksu Arıca et al. 2020; Bahramian et al. 2018; Gupta, A. et al. 2017; Muzaffar Tak and Hussain Chalkoo 2017). Further, lower vitamin D levels were reported in erosive OLP patients compared to non-erosive types, albeit not consistently at statistical significance (Aksu Arıca et al. 2020; Gupta, A. et al. 2017). In this study, we have demonstrated the independent role of vitamin D as a predictor of clinical severity accounting for a range of potential confounding variables associated with OLP.

Vitamin D is a pleiotropic hormone that exerts a wide range of physiological functions by binding to the vitamin D receptor (VDR) (Saeed et al. 2022). In vitro studies have shown that vitamin D/VDR signalling protects against OLP by suppressing inflammation and epithelial cell apoptosis (Du et al. 2017; Zhao et al. 2018; Zhao et al. 2019). In this study, we showed for that vitamin D was a robust predictor of OLP disease severity, suggesting that insufficient

vitamin D levels may contribute to disease progression. Vitamin D exhibits anti-inflammatory

properties through downregulation of Th1 and upregulation of Th2 responses (Saeed et al.

2022). Vitamin D/VDR signalling also suppresses apoptosis in oral keratinocytes by repressing

miR-802 expression (Zhao et al. 2019). Vitamin D deficiency in OLP may compromise the

protective effect of vitamin D/VDR signalling, resulting in increased apoptosis of oral

keratinocytes and contributing to the development of erosions or ulcerations seen in more

severe clinical presentations.

In patients with gingival manifestations of OLP, we showed a significant association between

gingival disease severity and plaque-induced gingivitis. This observation aligns with accepted

knowledge that pain associated with gingival OLP interferes with effective oral hygiene,

leading to plague accumulation and in turn exacerbating existing OLP lesions and vice versa

(Scribante et al. 2023). Extraoral lichen planus and insufficient vitamin D emerged as

significant predictors of gingival disease severity in our study. This finding suggests a potential

interplay between systemic and local factors influencing gingival health in OLP patients. It

highlights the need for a holistic approach addressing both local and systemic factors, for

example vitamin D supplementation, in optimising oral health outcomes of OLP patients.

Statistically significant relationships between haematinic factors and disease severity were not

consistently identified across all outcomes of disease severity used in this study. Specifically,

we observed a significant association between folate deficiency and OLP severity only when

this was measured by the REU score. This finding questions the role of haematinic

deficiencies as a predictor of disease severity, notwithstanding the limitations of this single

arm cross-sectional study. Further, our analysis did not identify a significant association

between stress and OLP severity. This could be attributed to the inherent limitations of self-

reported stress data, which are susceptible to recall bias. Likewise, we observed a statistically

significant association between hyperlipidaemia and OLP severity as measured by ODSS, but

12

the associated wide confidence intervals suggest data uncertainty.

This study highlights the importance of adequate vitamin D supplementation in OLP in the

population here described. Vitamin D deficiency is a global public health concern, affecting

individuals of all ages, including low-latitude regions with ample sunlight (Palacios and

Gonzalez 2015). On the other hand, geographical differences in the prevalence of vitamin D

deficiency partly dependent on sunlight exposure are well documented, for example in the

United Kingdom where prevalence is higher in the northern regions (Lin et al. 2021). To date,

no studies have formally assessed the relationship between sunlight exposure, the

subsequent impact on vitamin D status, and the geographical distribution of oral lichen planus.

A recent systematic review (González-Moles et al. 2021) reported the highest prevalence of

OLP in Europe compared to the global population. However, in nation-level analysis higher

OLP prevalences in European countries did not align with reduced sunlight exposure.

Future research should explore generalisability of the findings of this study to the wider

population as well as the biological mechanisms underlying the beneficial effects of vitamin D

in OLP. Furthermore, interventional studies are required to assess the therapeutic efficacy of

vitamin D supplementation in OLP to determine its clinical benefit and to optimise treatment

guidelines.

**Acknowledgement** 

We extend our sincere gratitude to the clinical and administrative staff of the Departments of

Oral Medicine and Oral & Maxillofacial Surgery at Aberdeen Royal Infirmary for their invaluable

assistance with patient recruitment and research visits. We are further indebted to all the

patients who generously participated, making this research possible. We also thank the

Medical Statistics team at the University of Aberdeen for their guidance with the statistical

analysis presented in the study.

Author contributions:

Sreedevi P. Unnikrishnan: contributed to data acquisition, analysis or interpretation of data and

drafted the manuscript; Janice Boggon: contributed to design and critically revised the

manuscript; Bernice Mclaughlin: contributed to design and critically revised the manuscript;

Maggie E. Cruickshank: contributed to conception, design, analysis or interpretation of data

and critically revised the manuscript; Rasha Abu-Eid: contributed to conception, design,

analysis or interpretation of data and critically revised the manuscript; Karolin Hijazi:

contributed to conception, design, analysis or interpretation of data and critically revised the

manuscript. All authors gave their final approval and agree to be accountable for all aspects

of the work.

**Conflicts of Interest** 

The authors declare no potential conflicts of interest with respect to the research, authorship,

and/or publication of this article.

**Funding** 

SPU is supported by the Elphinstone Scholarship scheme, University of Aberdeen.

Data availability statement

Pseudonymised data can be made available upon reasonable and FAIR-compliant requests

14

to the corresponding author.

perpetuity.
All rights reserved. No reuse allowed without permission.

#### References

- 1. Aksu Arıca D, Baykal Selçuk L, Örem A, Karaca Ural Z, Yaylı S, Bahadır S. 2020. Evaluation of serum vitamin D levels in patients with lichen planus. *Turkderm.* 54(4):138-142.
- 2. Baek K, Choi Y. 2017. The microbiology of oral lichen planus: Is microbial infection the cause of oral lichen planus? *Mol Oral Microbiol.* 33(1):22-28.
- 3. Bahramian A, Bahramian M, Mehdipour M, Falsafi P, Khodadadi S, Dabaghi Tabriz F, Deljavanghodrati M. 2018. Comparing vitamin D serum levels in patients with oral lichen planus and healthy subjects. *J Dent* (Shiraz).19(3):212-216.
- 4. Chapple ILC, Mealey BL, Dyke TE, Bartold PM, Dommisch H, Eickholz P, Geisinger ML, Genco RJ, Glogauer M, Goldstein M, et al. 2018. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 world workshop on the classification of periodontal and Peri-Implant diseases and conditions. *J. Periodontol.* 89(S1):S74-84.
- 5. Chaudhary S. 2004. Psychosocial stressors in oral lichen planus. *Aust Dent J.* 49(4):192-195.
- 6. Cheng YL, Gould A, Kurago Z, Fantasia J, Muller S. 2016. Diagnosis of oral lichen planus: A position paper of the american academy of oral and maxillofacial pathology. *Oral Surg Oral Med Oral Radiol*.122(3):332-54.
- 7. Cui A, Zhang T, Xiao P, Fan Z, Wang H, Zhuang Y. 2023. Global and regional prevalence of vitamin D deficiency in population-based studies from 2000 to 2022: A pooled analysis of 7.9 million participants. *Front Nutr* (*Lausanne*). 10:1070808.
- 8. Dave A, Shariff J, Philipone E. 2020. Association between oral lichen planus and systemic conditions and medications: Case–control study. *Oral Dis.* 27(3):515-524.
- 9. De Porras-Carrique T, Ramos-García P, González-Moles MÁ. 2023. Hypertension in oral lichen planus: A systematic review and meta-analysis. *Oral Dis* [epub ahead of print].
- 10. De Porras-carrique T, Ramos-garcía P, Aguilar-diosdado M, Warnakulasuriya S, González-moles MÁ. 2022. Autoimmune disorders in oral lichen planus: A systematic review and meta-analysis. *Oral Dis.* 29(4):1382-1394.
- 11. De Porras-Carrique T, González-Moles MÁ, Warnakulasuriya S, Ramos-García P. 2021. Depression, anxiety, and stress in oral lichen planus: A systematic review and meta-analysis. Clin Oral Investig. 26(2):1391-1408.
- 12. De Rossi SS, Ciarrocca K. 2014. Oral lichen planus and lichenoid mucositis. *Dent Clin N Am*.58(2):299-313.
- 13. Du J, Li R, Yu F, Yang F, Wang J, Chen Q, Wang X, Zhao B, Zhang F. 2017. Experimental study on 1,25(OH) 2 D 3 amelioration of oral lichen planus through regulating NF- κ B signaling pathway. *Oral Dis*. 23(6):770-778.
- 14. Escudier M, Ahmed N, Shirlaw P, Setterfield J, Tappuni A, Black MM, Challacombe SJ. 2007. A scoring system for mucosal disease severity with special reference to oral lichen planus. *Br J Dermatol*.157(4):765-70.
- 15. González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, González-Ruiz L, Ayén Á, Lenouvel D, Ruiz-Ávila I, Ramos-García P. 2021. Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. *Oral Dis.* 27(4):813-828.

perpetuity.
All rights reserved. No reuse allowed without permission.

- 16. Greene JC, Vermillion JR. 1964. The simplified oral hygiene index. *J Am Dent Assoc.* 68(1):7-13.
- 17. Gupta A, Sasankoti Mohan RP, Kamarthi N, Malik S, Goel S, Gupta S. 2017. Serum vitamin D level in oral lichen planus patients of north India- A casecontrol study. *J Dermatol Res Ther*. 1(2):19-35.
- 18. Gupta S, Jawanda MK. 2015. Oral lichen planus: An update on etiology, pathogenesis, clinical presentation, diagnosis and management. *Indian J Dermatol.* 60(3):222-9.
- 19. Lai YC, Yew YW, Schwartz RA. 2016. Lichen planus and dyslipidemia: A systematic review and meta-analysis of observational studies. *Int J Dermatology*. 55(5): e295-304.
- 20. Li D, Li J, Li C, Chen Q, Hua H. 2017. The association of thyroid disease and oral lichen planus: A literature review and meta-analysis. *Front Endocrinol (Lausanne)*. 8:310.
- 21. Lin L, Smeeth L, Langan S, Warren-Gash C. 2021. Distribution of vitamin D status in the UK: A cross-sectional analysis of UK biobank. *BMJ Open.* 11(1):e038503.
- 22. Lodi G, Carrozzo M, Furness S, Thongprasom K. 2012. Interventions for treating oral lichen planus: A systematic review. *Br J Dermatol*. 166(5):938-47.
- 23. Mallah N, Ignacio Varela-centelles P, Seoane-romero J, Takkouche B. 2021. Diabetes mellitus and oral lichen planus: A systematic review and meta-analysis. *Oral Dis.* 28(8):2100-2109.
- 24. Muzaffar Tak M, Hussain Chalkoo A. 2017. Vitamin d deficiency- a possible contributing factor in the aetiopathogenesis of oral lichen planus. *J Evolution Med Dent Sci.* 6(66):4769-4772.
- 25. Olson MA, Rogers RS, Bruce AJ. 2016. Oral lichen planus. *Clin Dermatol.* 34(4):495-504.
- 26. Otero Rey EM, Yáñez-busto A, Rosa Henriques IF, López-lópez J, Blanco-carrión A. 2018. Lichen planus and diabetes mellitus: Systematic review and meta-analysis. *Oral Dis.* 25(5):1253-1264.
- 27. Ower P. 2016. BPE guidelines: British society of periodontology revision 2016. *Dent Update*. 43(5):406-8.
- 28. Palacios C, Gonzalez L. 2015. Is vitamin D deficiency a major global public health problem? *J Steroid Biochem Mol Biol*.144:138-45.
- 29. Piboonniyom S, Treister N, Pitiphat W, Woo S. 2005. Scoring system for monitoring oral lichenoid lesions: A preliminary study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 99(6):696-703.
- 30. Saeed S, Choudhury P, Ahmad SA, Alam T, Panigrahi R, Aziz S, Kaleem SM, Priyadarshini SR, Sahoo PK, Hasan S. 2022. Vitamin D in the treatment of oral lichen planus: A systematic review. *Biomedicines*. 10(11):2964.
- 31. Scribante A, Pellegrini M, Li Vigni G, Pulicari F, Spadari F. 2023. Desquamative gingivitis, oral hygiene, and autoimmune oral diseases: A scoping review. *Appl Sci.* 13(18):10535.
- 32. Scully C, Carrozzo M. 2007. Oral mucosal disease: Lichen planus. *Br J Oral Maxillofac Surg.* 46(1):15-21.
- 33. Sun A, Wu YC, Wang JT, Liu BY, Chiang CP. 2000. Association of HLA-te22 antigen with anti-nuclear antibodies in chinese patients with erosive oral lichen planus. *Proc Natl Sci Counc Repub China B*. 24(2):63-9.

perpetuity.
All rights reserved. No reuse allowed without permission.

- 34. Tonetti MS, Greenwell H, Kornman KS. 2018. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J Periodontol.* 89(S1):S159-72.
- 35. Unnikrishnan SP, Rampersaud E, Mcgee A, Cruickshank ME, Abu-Eid R, Hijazi K. 2023. Disease severity scoring systems in mucosal lichen planus: A systematic review. *Oral Dis.* 29(8):3136-51.
- 36. Van Der Meij EH, Van Der Waal I. 2003. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. *J Oral Pathol Med.* 32(9):507-12.
- 37. Wiriyakijja P, Porter S, Fedele S, Hodgson T, McMillan R, Shephard M, Ni Riordain R. 2020. Validation of the HADS and PSS-10 and psychological status in patients with oral lichen planus. *Oral Dis.* 26(1):96-110.
- 38. Zhao B, Li R, Yang F, Yu F, Xu N, Zhang F, Ge X, Du J. 2018. LPS-induced vitamin D receptor decrease in oral keratinocytes is associated with oral lichen planus. *Sci Rep.* 8(1):763-9.
- 39. Zhao B, Xu N, Li R, Yu F, Zhang F, Yang F, Ge X, Li YC, Du J. 2019. Vitamin D/VDR signaling suppresses microRNA-802-induced apoptosis of keratinocytes in oral lichen planus. *FASEB J.* 33(1):1042-1050.

Table 1: General clinical characteristics of the study population.

Pemales, n (%)   65 (73)		
Age in years (median, [IQRs])         66 [58 to 73]           Oral Disease Severity Score (median, [IQRs])         10 [4 to 21]           Oral Disease Severity Score excluding pain score (median, [IQRs])         9 [4 to 19]           Gingival Oral Disease Severity Score (median, [IQRs])         1 [0 to 12]           [IQRs])         1 [0 to 12]           Reticulation, erythematous and ulcerative score (median, [IQRs])         .00 [.00 to 4.00]           Smoking pack years (median, [IQRs])         .00 [.00 to 4.00]           Smoking pack years (median, [IQRs])         .00 [.00 to 7.250]           Alcohol consumption (units per week) (median, [IQRs])         26.290 [23.525 to 31.730]           Di Item-Perceived Stress Scale score (mean ± standard deviation)         17 (19.1)           Entraoral lichen planus, n (%)         17 (19.1)           Genital lichen planus, n (%)         17 (19.1)           Genital lichen planus, n (%)         12 (13.5)           Cutaneous lichen planus, n (%)         12 (13.5)           Erosive clinical phenotype, n (%)         24 (27)           Involvement of typically spared oral sites, n (%)         19 (21.3)           Involvement of more than two oral subsites, n (%)         10 (21.3)           Piypertension, under treatment n (%)         25 (28.1)           Hyperlipidaemia, under treatment n (%)         25 (28.1) <t< th=""><th></th><th></th></t<>		
Oral Disease Severity Score (median, [IQRs])         10 [4 to 21]           Oral Disease Severity Score excluding pain score (median, [IQRs])         9 [4 to 19]           Gingival Oral Disease Severity Score (median, [IQRs])         1 [0 to 12]           Reticulation, erythematous and ulcerative score (median, [IQRs])         8 [4.5 to 20]           Pain score (median, [IQRs])         .00 [.00 to 4.00]           Smoking pack years (median, [IQRs])         .00 [.00 to 7.250]           Alcohol consumption (units per week) (median, [IQRs])         2.300 [.000 to 10.250]           Body Mass Index (kg/m²) (median, [IQRs])         26.290 [23.525 to 31.730]           Body Mass Index (kg/m²) (median, [IQRs])         26.290 [23.525 to 31.730]           Body Mass Index (kg/m²) (median, [IQRs])         17 (19.1)           Every Carrial lichen planus, n (%)         17 (19.1)           Extraoral lichen planus, n (%)         12 (13.5)           Cutaneous lichen planus, n (%)         46 (51.7)           Erosive clinical phenotype, n (%)         24 (27)           Involvement of typically spared oral sites, n (%)         19 (21.3)           Involvement of more than two oral subsites, n (%)         19 (21.3)           Hypertension, under treatment n (%)         25 (28.1)           Hypertension, under treatment n (%)         25 (24.7)           Coronary artery disease, n (%)		, ,
Oral Disease Severity Score excluding pain score (median, [IQRs])  Gingival Oral Disease Severity Score (median, [IQRs])  Reticulation, erythematous and ulcerative score (median, [IQRs])  Pain score (median, [IQRs])  Pain score (median, [IQRs])  Smoking pack years (median, [IQRs])  Alcohol consumption (units per week) (median, [IQRs])  Body Mass Index (kg/m²) (median, [IQRs])  Body Mass Index (kg/m²) (median, [IQRs])  Oral Ditem-Perceived Stress Scale score (mean ± standard deviation)  Extraoral lichen planus, n (%)  Genital lichen planus, n (%)  Gingival involvement in oral lichen planus, n (%)  Gingival involvement in oral lichen planus, n (%)  Involvement of typically spared oral sites, n (%)  Diabetes (type 2), under treatment n (%)  Hypertension, under treatment n (%)  Hypertension, under treatment n (%)  Sciendary  Sciendary  Sciendary  Sciendary  Sciendary  Sciendary  1 (1.1.)  Connective tissue diseases, n (%)  Sciendary  Sciendary  Sciendary  Remunical arthritis, Siggren's syndrome), n (%)  Sciendary  Sciendar		
(median, [IQRs])         1 [0 to 12]           Gingival Oral Disease Severity Score (median, [IQRs])         1 [0 to 12]           Reticulation, erythematous and ulcerative score (median, [IQRs])         8 [4.5 to 20]           Pain score (median, [IQRs])         .00 [.00 to 4.00]           Smoking pack years (median, [IQRs])         .00 [.00 to 7.250]           Alcohol consumption (units per week) (median, [IQRs])         .00 [.00 to 7.250]           Alcohol consumption (units per week) (median, [IQRs])         2.300 [.000 to 10.250]           Body Mass Index (kg/m²) (median, [IQRs])         26.290 [23.525 to 31.730]           10 item-Perceived Stress Scale score (mean ± standard deviation)         13.85±6.805           Straoral lichen planus, n (%)         17 (19.1)           Genital lichen planus, n (%)         12 [13.5]           Cutaneous lichen planus, n (%)         5 (5.6)           Gingival involvement in oral lichen planus, n (%)         46 (51.7)           Forsive clinical phenotype, n (%)         24 (27)           Involvement of typically spared oral sites, n (%)         19 (21.3)           Involvement of more than two oral subsites, n (%)         19 (21.3)           Pippertension, under treatment n (%)         12 (3.5)           Hypertension, under treatment n (%)         25 (28.1)           Hypertipidaemia, under treatment n (%)         20 (24.7) <td>, , , , , , , , , , , , , , , , , , , ,</td> <td></td>	, , , , , , , , , , , , , , , , , , , ,	
Reticulation, erythematous and ulcerative score (median, [IQRs])  Pain score (median, [IQRs])  Pain score (median, [IQRs])  Smoking pack years (median, [IQRs])  Body Mass Index (kg/m²) (median, [IQRs])  Body Mass Index (kg/m²) (median, [IQRs])  10 item-Perceived Stress Scale score (mean ± standard deviation)  Extraoral lichen planus, n (%)  Cutaneous lichen planus, n (%)  Cutaneous lichen planus, n (%)  Erosive clinical phenotype, n (%)  Involvement of typically spared oral sites, n (%)  Diabetes (type 2), under treatment n (%)  Lypertension, under treatment n (%)  Lyperlension, under treatment n (%)  Cerebrovascular disease, n (%)  Cerebrovascular disease, n (%)  Cerebrovascular diseases, n (%)  Scleroderma, n  Rheumatoid arthritis, n  Solgeran's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, n  1 (Sella disease, n  Alopecia areata, n  1 (Sella disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  I (Lichen sclerosus, n  1 (Lichen sclerosus, n  1 (Sella disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  I (Lichen sclerosus, n  1 (Lichen sclerosus)	,	9 [4 to 19]
(median, [IQRs])         .00 [.00 to 4.00]           Smoking pack years (median, [IQRs])         .00 [.00 to 7.250]           Alcohol consumption (units per week) (median, [IQRs])         2.300 [.000 to 10.250]           Body Mass Index (kg/m²) (median, [IQRs])         26.290 [23.525 to 31.730]           10 item-Perceived Stress Scale score (mean ± standard deviation)         13.85±6.805           Extraoral lichen planus, n (%)         17 (19.1)           Genital lichen planus, n (%)         12 (13.5)           Cutaneous lichen planus, n (%)         5 (5.6)           Gingival involvement in oral lichen planus, n (%)         46 (51.7)           Erosive clinical phenotype, n (%)         24 (27)           Involvement of typically spared oral sites, n (%)         19 (21.3)           Involvement of more than two oral subsites, n (%)         56 (62.9)           (%)         12 (13.5)           Hypertension, under treatment n (%)         12 (13.5)           Hypertension, under treatment n (%)         22 (24.7)           Coronary artery disease, n (%)         9 (10.1)           Cerebrovascular disease, n (%)         5 (5.6)           Inflammatory bowel disease, n (%)         5 (5.6)           Inflammatory bowel disease, n (%)         1 (1.1)           Connective tissue diseases (soleroderma, rheumatoid arthritis, n         2 </td <td></td> <td>1 [0 to 12]</td>		1 [0 to 12]
Smoking pack years (median, [IQRs])   .00 [.00 to 7.250]     Alcohol consumption (units per week) (median, [IQRs])   2.300 [.000 to 10.250]     IQRs])   26.290 [23.525 to 31.730]     10 item-Perceived Stress Scale score (mean ± standard deviation)   13.85±6.805     Extraoral lichen planus, n (%)   17 (19.1)     Cenital lichen planus, n (%)   5 (5.6)     Gingival involvement in oral lichen planus, n (%)   24 (27)     Involvement of typically spared oral sites, n (%)   19 (21.3)     Involvement of more than two oral subsites, n (%)   19 (21.3)     Involvement of more than two oral subsites, n (%)   25 (28.1)     Hypertension, under treatment n (%)   25 (28.1)     Hypertipidaemia, under treatment n (%)   9 (10.1)     Cerebrovascular disease, n (%)   9 (10.1)     Cerebrovascular disease, n (%)   1 (1.1)     Connective tissue diseases (scleroderma, nheumatoid arthritis, Sjogren's syndrome), n (%)     Scleroderma, n   1     Rheumatoid arthritis, n   2   2     Sjogren's syndrome, n   0   2     Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)   1     Psoriasis, n   2   2     Vitiligo, n   1   1     Lichen sclerosus, n   1     Lichen sclerosus, n   1	•	8 [4.5 to 20]
Alcohol consumption (units per week) (median, [IQRs])  Body Mass Index (kg/m²) (median, [IQRs])  10 item-Perceived Stress Scale score (mean ± standard deviation)  Extraoral lichen planus, n (%)  Genital lichen planus, n (%)  Cutaneous lichen planus, n (%)  Gingival involvement in oral lichen planus, n (%)  Erosive clinical phenotype, n (%)  Involvement of typically spared oral sites, n (%)  Diabetes (type 2), under treatment n (%)  Hypertension, under treatment n (%)  Hypertension, under treatment n (%)  Coronary artery disease, n (%)  Inflammatory bowel disease, n (%)  Scleroderma, n  Rheumatoid arthritis, Siggren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (sporiasis, vitiligo, alopecia areata, coeliac disease, n  Alopecia areata, coeliac disease, n  Vitiligo, n  I coeliac disease, n  Alopecia areata, n  Coeliac disease, n  Bullous pemphigoid, n  Lichen sclerosus, n  I clichen sclerosus, n  I clichen sclerosus, n  Bullous pemphigoid, n  I clichen sclerosus, n  I clichen sclerosus, n  I clichen sclerosus, n  I clichen sclerosus, n	Pain score (median, [IQRs])	.00 [.00 to 4.00]
IQRs  Body Mass Index (kg/m²) (median, [IQRs])   26.290 [23.525 to 31.730]   10 item-Perceived Stress Scale score (mean ± standard deviation)   13.85±6.805	Smoking pack years (median, [IQRs])	.00 [.00 to 7.250]
10 item-Perceived Stress Scale score (mean ± standard deviation)  Extraoral lichen planus, n (%)  Cenital lichen planus, n (%)  Cutaneous lichen planus, n (%)  Gingival involvement in oral lichen planus, n (%)  Erosive clinical phenotype, n (%)  Involvement of typically spared oral sites, n (%)  Diabetes (type 2), under treatment n (%)  Hypertension, under treatment n (%)  Eroronary artery disease, n (%)  Cerebrovascular disease, n (%)  Inflammatory bowel disease, n (%)  Scleroderma, n  Rheumatoid arthritis, n  Solgeren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, n  Psoriasis, n  2 Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Alulous pemphigoid, n  Lichen sclerosus, n  Bullous pemphigoid, n  Lichen sclerosus, n  1 Lichen sclerosus, n		2.300 [.000 to 10.250]
Standard deviation)  Extraoral lichen planus, n (%) 17 (19.1)  Genital lichen planus, n (%) 5 (5.6)  Cutaneous lichen planus, n (%) 5 (5.6)  Gingival involvement in oral lichen planus, n (%) 46 (51.7)  Erosive clinical phenotype, n (%) 24 (27)  Involvement of typically spared oral sites, n (%) 19 (21.3)  Involvement of more than two oral subsites, n (%) 19 (21.3)  Involvement of more than two oral subsites, n (%) 19 (21.3)  Involvement of more than two oral subsites, n (%) 12 (13.5)  Hypertension, under treatment n (%) 25 (28.1)  Hyperlipidaemia, under treatment n (%) 22 (24.7)  Coronary artery disease, n (%) 9 (10.1)  Cerebrovascular disease, n (%) 1 (1.1)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n 1  Rheumatoid arthritis, n 2  Sjogren's syndrome, n 2  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n 1  Alopecia areata, n 1  Coeliac disease, n 4  Pernicious anaemia, n 3  Bullous pemphigoid, n 1  Lichen sclerosus, n 1	Body Mass Index (kg/m²) (median, [IQRs])	26.290 [23.525 to 31.730]
Extraoral lichen planus, n (%) 17 (19.1)  Genital lichen planus, n (%) 12 (13.5)  Cutaneous lichen planus, n (%) 5 (5.6)  Gingival involvement in oral lichen planus, n (%) 46 (51.7)  Erosive clinical phenotype, n (%) 24 (27)  Involvement of typically spared oral sites, n (%) 19 (21.3)  Involvement of more than two oral subsites, n (%) 19 (21.3)  Involvement of more than two oral subsites, n (%) 25 (28.1)  Hypertension, under treatment n (%) 25 (28.1)  Hyperlipidaemia, under treatment n (%) 9 (10.1)  Cerebrovascular disease, n (%) 9 (10.1)  Cerebrovascular disease, n (%) 1 (1.1)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n 1  Rheumatoid arthritis, n 2  Sjogren's syndrome, n 2  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n 1  Alopecia areata, n 1  Coeliac disease, n 4  Pernicious anaemia, n 3  Bullous pemphigoid, n 1  Lichen sclerosus, n 1	•	13.85±6.805
Genital lichen planus, n (%) Cutaneous lichen planus, n (%) Gingival involvement in oral lichen planus, n (%) Erosive clinical phenotype, n (%) Erosive clinical phenotype, n (%) Prosive clinical phenotype, n (%)  Involvement of typically spared oral sites, n (%) Involvement of more than two oral subsites, n (%) Involvement of more than two oral subsites, n (%) Diabetes (type 2), under treatment n (%) Diabetes (type 2), under treatment n (%) Hypertension, under treatment n (%) Erosive clinical phenotype, n (%)  Evaluation of the provided in the provided	•	17 (19.1)
Cutaneous lichen planus, n (%) 5 (5.6) Gingival involvement in oral lichen planus, n (%) 46 (51.7) Erosive clinical phenotype, n (%) 24 (27) Involvement of typically spared oral sites, n (%) 19 (21.3) Involvement of more than two oral subsites, n (%) Diabetes (type 2), under treatment n (%) 12 (13.5) Hypertension, under treatment n (%) 25 (28.1) Hyperlipidaemia, under treatment n (%) 9 (10.1) Coronary artery disease, n (%) 9 (10.1) Cerebrovascular disease, n (%) 1 (1.1) Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%) Scleroderma, n 1 Rheumatoid arthritis, n 2 Sjogren's syndrome, n 2 Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%) Psoriasis, n 2 Vitiligo, n 1 Alopecia areata, n 1 Coeliac disease, n 4 Pernicious anaemia, n 3 Bullous pemphigoid, n 1 Lichen sclerosus, n 1		
Gingival involvement in oral lichen planus, n (%) 46 (51.7)  Erosive clinical phenotype, n (%) 24 (27) Involvement of typically spared oral sites, n (%) 19 (21.3) Involvement of more than two oral subsites, n (%) 56 (62.9) (%) Diabetes (type 2), under treatment n (%) 12 (13.5) Hypertension, under treatment n (%) 25 (28.1) Hyperlipidaemia, under treatment n (%) 9 (10.1) Coronary artery disease, n (%) 9 (10.1) Cerebrovascular disease, n (%) 5 (5.6) Inflammatory bowel diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%) Scleroderma, n 1 Rheumatoid arthritis, n 2 Sjogren's syndrome, n 2 Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%) Psoriasis, n 2 Vitiligo, n 1 Alopecia areata, n 1 Coeliac disease, n 4 Pernicious anaemia, n 3 Bullous pemphigoid, n 1 Lichen sclerosus, n 1		
Erosive clinical phenotype, n (%) 24 (27) Involvement of typically spared oral sites, n (%) 19 (21.3) Involvement of more than two oral subsites, n (%) Diabetes (type 2), under treatment n (%) 12 (13.5) Hypertension, under treatment n (%) 25 (28.1) Hyperlipidaemia, under treatment n (%) 9 (10.1) Coronary artery disease, n (%) 9 (10.1) Cerebrovascular disease, n (%) 1 (1.1) Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%) Scleroderma, n 1 Rheumatoid arthritis, n 2 Sjogren's syndrome, n 2 Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%) Psoriasis, n 1 Coeliac disease, n 4 Pernicious anaemia, n 3 Bullous pemphigoid, n 1 Lichen sclerosus, n 1		
Involvement of typically spared oral sites, n (%) Involvement of more than two oral subsites, n (%) Diabetes (type 2), under treatment n (%)  Pypertension, under treatment n (%)  Hyperlipidaemia, under treatment n (%)  Coronary artery disease, n (%)  Inflammatory bowel disease, n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1 (2.1.3.5)  12 (21.3.5)  12 (13.5)  12 (10.1.5)  13 (10.1.1)  14 (1.1.1)  15 (5.6)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (5.6)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.3.5)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  18 (1.1.1)  19 (1.1.1)  10 (1.1.1)  10 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  11 (1.1.1)  12 (1.1.1)  13 (1.1.1)  14 (1.1.1)  15 (1.1.1)  16 (1.1.1)  17 (1.1.1)  18 (1.1.1)  18 (1.1.1)  18 (1.1.1)  18 (1.1.1)  18 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1.1)  19 (1.1		
Involvement of more than two oral subsites, n (%)  Diabetes (type 2), under treatment n (%)  Hypertension, under treatment n (%)  Hyperlipidaemia, under treatment n (%)  Coronary artery disease, n (%)  Cerebrovascular disease, n (%)  Inflammatory bowel disease, n (%)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Q  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n		
Diabetes (type 2), under treatment n (%)  Hypertension, under treatment n (%)  Everebrovascular disease, n (%)  Inflammatory bowel diseases, n (%)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1 (2 (3.13.5)  2 (24.7)  2 (24.7)  2 (5.6)  1 (1.1)  2 (5.6)  1 (1.1)  2 (5.6)  1 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  2 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  5 (5.6)  1 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  4 (1.1)  5 (5.6)  1 (1.1)  4 (1	Involvement of more than two oral subsites, n	
Hypertension, under treatment n (%) 25 (28.1) Hyperlipidaemia, under treatment n (%) 22 (24.7)  Coronary artery disease, n (%) 9 (10.1)  Cerebrovascular disease, n (%) 5 (5.6) Inflammatory bowel disease, n (%) 1 (1.1)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n 1  Rheumatoid arthritis, n 2 Sjogren's syndrome, n 2  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n 2  Vitiligo, n 1  Alopecia areata, n 1  Coeliac disease, n 4  Pernicious anaemia, n 3  Bullous pemphigoid, n 1  Lichen sclerosus, n 1		12 (13.5)
Hyperlipidaemia, under treatment n (%)  Coronary artery disease, n (%)  Cerebrovascular disease, n (%)  Inflammatory bowel disease, n (%)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  2  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n		
Coronary artery disease, n (%) 9 (10.1)  Cerebrovascular disease, n (%) 5 (5.6)  Inflammatory bowel disease, n (%) 1 (1.1)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n 1  Rheumatoid arthritis, n 2  Sjogren's syndrome, n 2  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n 2  Vitiligo, n 1  Alopecia areata, n 1  Coeliac disease, n 4  Pernicious anaemia, n 3  Bullous pemphigoid, n 1  Lichen sclerosus, n 1		
Cerebrovascular disease, n (%) 5 (5.6)  Inflammatory bowel disease, n (%) 1 (1.1)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n 1  Rheumatoid arthritis, n 2  Sjogren's syndrome, n 2  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n 2  Vitiligo, n 1  Alopecia areata, n 2  Coeliac disease, n 4  Pernicious anaemia, n 3  Bullous pemphigoid, n 1  Lichen sclerosus, n 1		
Inflammatory bowel disease, n (%)  Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1 (1.1)  1 (1.1)  1 (1.1)  1 (1.1)  1 (1.1)  2 (1.1)  2 (1.1)  1 (1.1)		
Connective tissue diseases (scleroderma, rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Q  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  1  Lichen sclerosus, n		
rheumatoid arthritis, Sjogren's syndrome), n (%)  Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  2  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  Lichen sclerosus, n		
Scleroderma, n  Rheumatoid arthritis, n  Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1	•	
Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  2  Lichen sclerosus, n  2  Lichen sclerosus, n  2  Lichen sclerosus, n  1  1  1  1  1  1  1  1  1  1  1  1  1		1
Sjogren's syndrome, n  Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  2  11(12.4)	Rheumatoid arthritis, n	2
Other autoimmune diseases (psoriasis, vitiligo, alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  2  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  11(12.4)  11(12.4)  11(12.4)  11  12  14  15  16  17  17  18  18  18  18  18  18  18  18		2
alopecia areata, coeliac disease, pernicious anaemia, bullous pemphigoid, lichen sclerosus), n (%)  Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1		11(12.4)
n (%) Psoriasis, n  2 Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  Lichen sclerosus, n  2  1  1  Lichen sclerosus, n  1  Lichen sclerosus, n		
n (%) Psoriasis, n  2 Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  Lichen sclerosus, n  2  1  1  Lichen sclerosus, n  1  Lichen sclerosus, n		
Psoriasis, n  Vitiligo, n  Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  2  4  1  Lichen sclerosus, n  2  1  Lichen sclerosus, n  1  Lichen sclerosus, n  2  1  1  Lichen sclerosus, n		
Alopecia areata, n 1 Coeliac disease, n 4 Pernicious anaemia, n 3 Bullous pemphigoid, n 1 Lichen sclerosus, n 1		2
Alopecia areata, n  Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  1  Lichen sclerosus, n  1  Lichen sclerosus, n	Vitiligo, n	1
Coeliac disease, n  Pernicious anaemia, n  Bullous pemphigoid, n  Lichen sclerosus, n  4  1  Lichen sclerosus, n	Alopecia areata, n	1
Bullous pemphigoid, n 1 Lichen sclerosus, n 1		4
Lichen sclerosus, n 1	Pernicious anaemia, n	3
Lichen sclerosus, n 1	Bullous pemphigoid, n	1
Hypothyroidism, under treatment n (%) 18 (20.2)	Lichen sclerosus, n	1
	Hypothyroidism, under treatment n (%)	18 (20.2)

Overall Oral Hygiene Index-Simplified, n (%)					
Edentulous/missing index teeth	31 (34.8)				
Good	53 (59.6)				
Fair	5 (5.6)				
Poor	0				
Gingivitis (≥10% bleeding sites), n (%)	17 (19.1)				
Periodontitis, n (%)	46 (51.7)				
Recent use of oral topical steroids (within past	33 (37.1)				
two months), n (%)					
Coexisting fungal infection, n (%)	5 (5.6)				
Insufficient vitamin D levels (25-50 nmol/L), n	29 (32.6)				
(%)					
Deficient vitamin D levels (<25 nmol/L), n (%)	8 (9)				
On replacement therapy for vitamin B12, n (%)	18 (20.2)				
Deplete vitamin B12 levels, n (%)	13 (14.6)				
On replacement therapy for ferritin, n (%)	5 (5.6)				
Deplete ferritin levels, n (%)	4 (4.5)				
On replacement therapy for folate, n (%)	5 (5.6)				
Deplete folate levels, n (%)	3 (3.4)				

Abbreviation: IQR, Interquartile Range.

Table 2: Hierarchical linear regression of clinical indicators of oral lichen planus disease severity.

Basic model I	Disea	se severity plan		lichen	Disease severity of oral lichen planus				Disease severity of oral lichen planus			
	(measured as total ODSS)				(measured as ODSS excluding pain score)			(measured as REU scoring system)				
	β	(95% CI)	6 р		β	(95% CI)			β	(95% CI	)	р
Age	134	(335 .067)	19	0	101	(281 - .078)	.26	4	094	(273 - .085)		.300
Gender	1.294	(-3.116 5.704)		1	1.029	(-2.912 - 4.970)	.60	5	1.854	(-2.068 - 5.776)		.350
Type 2 Diabetes Mellitus, under treatment	1.726	(-5.216 8.668)		2	1.784	(-4.420 - 7.988)	.56	9	.490	(-5.684 - 6.664)		.875
Hypothyroidism, under treatment	-3.068	(-8.63 <sup>4</sup> 2.497)		6	-2.568	(-7.631 - 2.494)	.31	6	-1.395	(-6.345 - 3.555)		.576
Hyperlipidaemia, under treatment	6.548	(.165 - 12.931		4*	5.305	(400 - 11.009)	.06	8	4.850	(827 - 10.527)		.093
Number of medications associated with lichenoid reactions	-2.999	(-6.719 .721)	9 - 11.	3	-2.995	(-6.320 - .329)	.07	7	-3.504	(-6.813 - .196)	-	.038*
Erosive clinical phenotype	11.758	(7.055 16.461		01***	9.747	(5.544 - 13.951)	<.00	01*	12.681	(8.499 - 16.864)		<.001***
Use of topical oral steroids, within the past two months	4.926	(.705 - 9.146)		3*	3.310	(462 - 7.082)	.08	5	3.560	(193 - 7.314)		.063
Adjusted R <sup>2</sup> for model I	.330		I		.275				.361		L	
p value for model I	< 0.001***				<0.001***				<0.001***			
Subsequent models (II to VIII)	Disease severity of oral lichen planus (measured by total ODSS)				Disease severity of oral lichen planus (measured by ODSS excluding pain score)				Disease severity of oral lichen planus (measured by REU scoring system)			
	β	(95% CI)	р	adj. R²	β	(95% CI)	р	adj. R²	β	(95% CI)	р	adj. R²
Model II (model I + 10 item-Perceived Stress Scale score)	.041	(271 - .352)	.796	.323	027	(306 - .251)	.845	.266	026	(303 - .251)	.852	.353
Model III (model I + extraoral manifestations of lichen planus)	5.766	(.744 - 10.788)	.025*	.364	5.474	(1.005 - 9.943)	.017*	.317	4.226	(287 - 8.740)	.066	.380
Model IV (model I + involvement of typically spared oral mucosal sites)	9.564	(4.873 - 14.254)	<.001* **	.439	8.191	(3.963 - 12.418)	<.001*	.382	8.127	(3.918 - 12.337)	<.001	* .455
Model V (model I + vitamin D) Vitamin D insufficiency	5.490	(1.136 - 9.844)	.014*	.375	5.043	(1.168 - 8.919)	.011*	.329	3.441 7.097	(462 - 7.344)	.083	.394
Vitamin D deficiency	6.400	(770 - 13.570)	.079		6.114	(268 - 12.496)	.060			(.670 - 13.524)	.031*	:
Model VI (model I + vitamin B12)	2.887		.283		1.300		.589		373		.876	

On vitamin B12		(-2.425 -		.324		(-3.475 -		.260		(-5.131 -		.346
replacement therapy	202	8.199)			1.47	6.076)			0.42	4.385)		
	302		.921		147		.957		943		.730	
Deplete vitamin B12		(-6.353 -	.521			(-5.586 -	.557			(-6.363 -	.730	
•		5.749)				5.293)				4.477)		
Model VII (model I + ferritin) On ferritin replacement therapy	2.141	(-6.900 - 11.183)	.639	.318	1.268	(-6.800 - 9.335)	.755	.264	263	(-8.298 <i>-</i> 7.772)	.948	.350
Deplete ferritin	-2.431	(-12.453 - 7.591)	.631		-3.495	(-12.438 - 5.448)	.439		-3.508	(-12.415 - 5.399)	.435	
Model VIII (model I + folate) On folate replacement therapy	-6.742	(-15.560 - 2.076)	.132		-7.361	(-15.225 - .502)	.066		-4.930	(-12.689 - 2.829)	.210	
Deplete folate	-8.548	(-20.789 - 3.694)	.168	.349	-5.835	(-16.752 - 5.082)	.291	.298	-11.404	(-22.175 633)	.038*	.391

Abbreviations: ODSS, Oral Disease Severity Score; REU, Reticular/hyperkeratotic, Erosive/erythematous, Ulcerative scoring system; adj. R<sup>2</sup>, Adjusted Coefficient of Determination; β, Unstandardised Regression Coefficient; CI, Confidence Interval. \* p <0.05, \*\* p<0.01, \*\*\* p<0.001.

Table 3: Hierarchical linear regression of clinical indicators of gingival disease severity (n=89).

Basic model I	Gingival disease severity of oral lichen planus							
		/al ODSS)						
	β	(95% CI)	р					
Age	024	(170122)	.746					
Gender	.242	(-3.086 - 3.569)	.885					
Type 2 Diabetes Mellitus, under treatment	2.536	(-2.172 – 7.243)	.287					
Hypothyroidism, under treatment	-1.919	(-5.845 - 2.006)	.334					
Dental plaque induced gingivitis based on bleeding on probing	4.833	(.600 - 8.333) .024*						
Presence of periodontitis	1.388	8 (-1.676 - 4.452) .370						
Erosive clinical phenotype	3.425	5 (.021 – 6.830) .049*						
Use of topical oral steroids, within the past two months	1.141	(-1.965 - 4.247) .467						
Adjusted R <sup>2</sup> for model I	.100							
p value for model I	.034*							
Subsequent models	Gingiva	al disease severity of	oral lichen	planus				
(II to VI)	(measured as Gingival ODSS)							
	β	β (95% CI) p adj. F						
Model II (model I + extraoral manifestations of lichen planus)	5.052	(1.072 - 9.032)	.014*	.157				
Model III (model I + vitamin D)								
Vitamin D insufficiency	4.732	(1.541 - 7.923)	.004**	.176				
Vitamin D deficiency	3.842	(-1.385 - 9.070)	.147					
Model IV (model I + vitamin B12)		,,						
On vitamin B12 replacement therapy	1.349	(-2.633 - 5.332)	.502	.083				
Deplete vitamin B12	301	(-4.727 - 4.125)	.893					
Model V (model I + ferritin)								
iviouei v (model I + lerrium)		i i	1	1				
On ferritin replacement therapy	2.488	(-4.257 - 9.232)	.465	.089				
·				.089				
On ferritin replacement therapy	2.488	(-4.257 - 9.232) (-10.179 - 5.014)	.465 .501	.089				
On ferritin replacement therapy  Deplete ferritin				.103				

Abbreviations: ODSS, Oral Disease Severity Score; adj. R2, Adjusted Coefficient of Determination; β, Unstandardised Regression Coefficient; CI, Confidence Interval. \* p <0.05, \*\* p<0.01, \*\*\* p<0.001.